Panels A-L show single confocal planes from third instar wing imaginal discs. (A) Mosaic of RpS3+/- and RpS3+/+ cells. p-eIF2α levels were increased in RpS3+/- cells (see A’). (B) Mosaic of RpS18+/- and RpS18+/+ cells. p-eIF2α levels were increased in RpS18+/- cells (see B’). (C) Mosaic of RpS3+/-Xrp1+/-and RpS3+/+Xrp-/- cells. p-eIF2α levels were unaffected in RpS3+/- cells when Xrp1 was mutated (see C’). (D) Mosaic of RpS17+/- and RpS17+/+ cells (the latter brighter white, having two copies of β-gal transgene). p-eIF2α levels were increased in RpS17+/- cells (see D’). (E) Mosaic of RpS17+/- and RpS17+/+ cells in an Xrp1+/- disc, (RpS17+/+ brighter white, having two copies of β-gal transgene). p-eIF2α levels were unaffected in RpS17+/- cells (see E’). (F) Clones of cells expressing Irbp18 RNAi in a RpS17+/- wing disc in white. p-eIF2α levels were reduced by Irbp18 knock-down (see F’). (G) Clones of cells expressing Irbp18 RNAi in a RpS17+/- wing disc in white. Translation rate was restored by Irbp18 knock-down (see G’). (H) Cells over-expressing PPP1R15 in the posterior compartment of a RpS3+/- wing disc in white. p-eIF2α levels were reduced by PPP1R15 over-expression (see H’). (I). Cells over-expressing PPP1R15 in the posterior compartment of a RpS18+/- wing disc in white. p-eIF2α levels were reduced by PPP1R15 over-expression (see I’). (J) Cells expressing PERK RNAi in the posterior compartment of a RpS3+/- wing disc in white. p-eIF2α levels were reduced by PERK knock-down (see J’). (K). Cells expressing PERK RNAi in the posterior compartment of a RpS18+/- wing disc in white. p-eIF2α levels were reduced by PERK knock-down (see K’). (L) Clones of cells expressing PERK RNAi in a RpS18+/- wing disc in white. Translation rate was restored by PERK knock-down (see L’). (M) Neutral clones expressing or lacking LacZ expression did not affect p-eIF2α levels (see M’). (N) Neutral clones expressing or lacking LacZ expression did not affect OPP incorporation (see N’). Genotypes: A: p{hs:FLP}/ p{hs:FLP}; FRT82 RpS3 p{arm:LacZ} /FRT82B, B: p{hs:FLP}/ p{hs:FLP}; FRT42 RpS18 p{Ubi:GFP}/FRT42, C: p{hs:FLP}/ p{hs:FLP}; FRT82 RpS3 p{arm:LacZ} /FRT82B Xrp1M2-73, D: p{hs:FLP}/ p{hs:FLP}; RpS17 FRT80B/p{arm:LacZ} FRT80B, E: p{hs:FLP}/ p{hs:FLP}; RpS17 FRT80B/p{arm:LacZ} FRT80B Xrp1M2–73, F-G: p{hs:FLP}/+; RpS17, act> CD2> Gal4, UAS-GFP /UAS- RNAiIrbp18, H: en-GAL4, UAS-GFP /UAS-PPP1R15; FRT82 RpS3/+, I: RpS18-,en-GAL4, UAS-GFP /UAS-PPP1R15, J: en-GAL4, UAS-GFP / UAS- RNAiPERK; FRT82 RpS3/+, K: RpS18-,en-GAL4, UAS-GFP /UAS- RNAiPERK, L: p{hs:FLP}/+; UAS- RNAiPERK / RpS18-; act> CD2> Gal4, UAS-His-RFP/+, M, N: p{hs:FLP}/ p{hs:FLP}; FRT80B/p{arm:LacZ} FRT80B.